Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through collabraotion, Neurocrine will to focus on the development and commercialization of VY-FXN01, which helps to restore FXN protein levels. It is being evaluated in the treatment of Friedreich’s ataxia.
Lead Product(s): VY-FXN01
Therapeutic Area: Genetic Disease Product Name: VY-FXN01
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Voyager Therapeutics, Inc
Deal Size: $1,865.0 million Upfront Cash: $165.0 million
Deal Type: Collaboration February 26, 2024
Details:
NBI-74788 (crinecerfont) is an investigational, oral, selective CRF1 antagonist being developed to reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of congenital adrenal hyperplasia.
Lead Product(s): Crinecerfont
Therapeutic Area: Genetic Disease Product Name: NBI-74788
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
Ingrezza (valbenazine) a new sprinkle formulation of capsules PDUFA target action date of April 30, 2024 and it is selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. FDA for the treatment chorea associated with Huntington's disease (HD).
Lead Product(s): Valbenazine Tosylate
Therapeutic Area: Neurology Product Name: Ingrezza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
NBI-74788 (crinecerfont) s an investigational, oral, selective CRF1 antagonist being developed to reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of congenital adrenal hyperplasia.
Lead Product(s): Crinecerfont
Therapeutic Area: Genetic Disease Product Name: NBI-74788
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.
Lead Product(s): NBI-1117570
Therapeutic Area: Neurology Product Name: NBI-1117570
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Sosei Heptares
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
INGREZZA® (valbenazine) Capsules is the selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD).
Lead Product(s): Valbenazine Tosylate
Therapeutic Area: Neurology Product Name: Ingrezza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
Under the research collaboration, Sentia’s proprietary peptide-based platform will be used to discover novel compounds as corticotropin-releasing factor receptor antagonist for the treatment of hypothalamic-pituitary-adrenal axis modulated diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Recipient: Sentia Medical Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration February 14, 2023
Details:
Under the collaboration, Neurocrine will receive worldwide rights to Voyager’s GBA1 gene therapy program for Parkinson’s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare CNS targets.
Lead Product(s): GBA1-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Voyager Therapeutics, Inc
Deal Size: $1,675.0 million Upfront Cash: $175.0 million
Deal Type: Collaboration January 09, 2023
Details:
The sNDA for valbenazine for the treatment of chorea associated with Huntington disease is supported by data from two clinical studies, including the Phase 3 study and the on-going KINECT-HD2 open-label rollover study, with more than 150 patients with Huntington disease.
Lead Product(s): Valbenazine Tosylate
Therapeutic Area: Genetic Disease Product Name: Ingrezza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
NBI-827104 is an investigational, potent, selective, and orally active brain-penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) in development for the potential treatment of EE-CSWS.
Lead Product(s): NBI-827104
Therapeutic Area: Neurology Product Name: NBI-827104
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022